Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $556.75, up 1.66% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported $12.0B revenue and $3.95B net income for 2025, with a robust 35% net margin, though recent quarterly EPS results were mixed. The acquisition of Crinetics Pharmaceuticals and raised 2026 sales guidance signal growth initiatives.
Outlook remains positive given Wall Street's 84% buy rating and a $548.78 consensus price target, but risks include competitive pressures in core markets and earnings volatility. The stock's valuation at 32.43x P/E requires sustained execution to justify further upside.
Read full analysis

Key Stats

  • Market Cap
    $141.42B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $376.62
  • Typical Hold Time
    -
  • Enterprise Value
    $135.55B
  • Div Yield
    -
  • Trading Activity
    -
$551.37
52W Low: $376.62
24 Sep 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $376.62 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Federal regulators investigate Tesla's Cybercab launch without steering wheel approval

Tesla launched its Cybercab, a vehicle without a steering wheel or pedals, by self-certifying its legality without prior regulator approval. The National Highway Traffic Safety Administration (NHTSA) has opened an audit to examine Tesla's certificati...

Market News
4 hours ago
24/7 Wall Street
Bearish
news icon
Federal regulators investigate Tesla's Cybercab launch without steering wheel approval

Avalo Therapeutics secures $472M funding, advancing Phase 3 trials for hidradenitis suppurativa drug abdakibart.

Avalo Therapeutics (AVTX) has raised $472 million, ensuring funding through 2029 to support its registrational-stage biotech development. The company’s lead drug, abdakibart, showed strong Phase II results for treating hidradenitis suppurativa, with ...

Market News
4 hours ago
Seeking Alpha
Bullish
news icon
Avalo Therapeutics secures $472M funding, advancing Phase 3 trials for hidradenitis suppurativa drug abdakibart.

AMC stock jumps 6% as CEO criticizes Robinhood's tokenized shares, sparking market split.

AMC Entertainment's CEO Adam Aron publicly condemned Robinhood's tokenized shares, calling them illegal and unauthorized by AMC. This criticism caused AMC's stock to rise 6%, while Robinhood's shares fell 3% amid a quiet market. Robinhood's tokens of...

Market News
4 hours ago
24/7 Wall Street
Neutral
AMC stock jumps 6% as CEO criticizes Robinhood's tokenized shares, sparking market split.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $141.42B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $376.62
  • Typical Hold Time
    -
  • Enterprise Value
    $135.55B
  • Div Yield
    -
  • Trading Activity
    -
$551.37
52W Low: $376.62
24 Sep 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $376.62 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!